GlassScriptPhysician profile
Koky Sang
NPI 1821294273
$6,299.86
in general payments reported to CMS, 2019-2025
17 companies · $803 in 2025
The $803 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,018 · 2020: $609 · 2021: $656 · 2022: $1,028 · 2023: $889 · 2024: $297 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,410.53 | 2019-2025 | Vemlidy |
| Novo Nordisk INC | $750.62 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $578.98 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $408.68 | 2019-2021 | |
| Lilly USA, LLC | $399.46 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $375.01 | 2022-2023 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.43 | 2019-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $250.00 | 2021-2022 | |
| Abbvie INC. | $147.99 | 2019-2023 | Vraylar |
| Genzyme Corporation | $145.70 | 2023 | |
| Merck Sharp & Dohme LLC | $125.00 | 2019 | |
| Allergan, INC. | $125.00 | 2020 | |
| Avanir Pharmaceuticals, INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2025 | Breztri |
| Pfizer INC. | $23.20 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $14.55 | 2019 | |
| Alkermes, INC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Koky Sang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.